Scientific American recently published a feature on wireless enabled and needle-free, continuous blood glucose monitoring company Echo Therapeutics, which was one of the few startups in wireless health that announced venture capital investment last year. Echo is currently seeking NDA clearance from the FDA. According to Scientific American, Echo's offering, Symphony tCGM, has three distinct...
